Feb 15 2013
For FY2012 Health Robotics today reported 39 new Robot sales [22 for Oncology, and 17 for non-hazardous IVs] plus 67 i.v.SOFT workflow software contracts, making 2012 yet another record year. For 4Q2012, the company reported 27 new contracts, including 11 I.V.
Robots (5 for Oncology Therapy, and 6 for non-hazardous IVs) and 16 i.v.SOFT workflow software agreements, continuing its 4-year supremacy of the world's Sterile Compounding Automation market. Now reaching over 350 total installations in the world [including over 90% of Oncology IV Robots global market share, and over 80% of total IV Robots global market share], Health Robotics continued to benefit in 2012 from its transition to a direct sales and service approach, now accounting for the majority of its gross revenues and profits.
Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "I'm very pleased with 2012 results, especially considering my 5-month medical leave of absence, and the effects of global economic crisis in some regions of the world. Auspiciously, Health-System pharmacists continue to recognize the undeniable fact that Health Robotics' second generation modular architecture of integrated and networked medical devices are fully automated, offer 3 to 4 times faster speed/throughput, for less than half the price, size, and weight than any of its global competitors[1], and delivering payback periods/R.O.I. of less than 1 year."
During last quarter, Health Robotics and/or some of its global partners signed up 27 new installations under contract at: Brigham & Women's Hospital, LeeSar Sterile Compounding Center (Florida), University of Tennessee Medical Center, University of Chicago Hospital, Hospital of the University of Pennsylvania, University Hospital of Ghent (Belgium), Goes Scheldezoom (Netherlands), Hamad Medical Corporation' Al-Wakrah Hospital (Qatar), King Khaled Hospital of the Ministry of Health (Hail, Saudi Arabia), and Etlik Hospital (Turkey), amongst others.
Mr. DeViedma concluded: "Health Robotics' 4Q and full year performance reflects a healthy mix of additional Robot and IV workflow sales to its pre-existing customers, as well as new sales to new Health-System pharmacies. Of particular interest to me is the expansion into Saudi Arabia and Qatar by replacing Olayan-AHCSC due to its poor service record and customer complaints, the explosion in i.v.SOFT contracts in USA and Benelux, and finally the replacement of CytoCare with the launch of i.v.STATION ONCO in selected countries where syringes and IV Bags are the norm, instead of the IV Bottles still supported by the CytoCare robot."